View Older Stories View More Recent Stories

Jun 25, 2020 08:45AM VolitionRx Releases Business Update Video and Announces Addition to the Russell 3000® and Russell Microcap® Indexes
May 27, 2020 08:45AM Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference
May 22, 2020 04:01PM VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock
May 20, 2020 08:47AM Volitionrx Limited (VNRX) Prices 4.37M Share Common Stock Offering at $2.75/sh
May 20, 2020 08:45AM VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock
May 19, 2020 04:02PM Volitionrx Limited (VNRX) to Offer Common Stock
May 19, 2020 04:01PM VolitionRx Announces Proposed Underwritten Public Offering of Common Stock
May 13, 2020 05:00PM VolitionRx To Present First Data on Nu.Q™ Capture Performance and Nu.Q™ Assay Performance in Lung Cancer and Blood Cancer at the 2020 ASCO Annual Meeting
May 7, 2020 04:10PM VolitionRx Limited Announces First Quarter 2020 Financial Results and Business Update
May 5, 2020 08:30AM VolitionRx Limited Schedules First Quarter 2020 Earnings Conference Call and Business Update
Apr 29, 2020 08:30AM Volition's Nu.Q™ Vet Assay Detects Two Common Canine Cancers
Apr 23, 2020 08:30AM Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies
Mar 10, 2020 08:45AM VolitionRx Limited Releases Annual Corporate Brochure and Video
Mar 3, 2020 08:30AM VolitionRx Limited to Present at Conferences in March 2020
Feb 20, 2020 04:10PM VolitionRx Limited Announces Full Fiscal Year 2019 Financial Results and Business Update
Feb 18, 2020 04:10PM VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update
Feb 18, 2020 08:30AM Volition Unveils Its Epigenetic Toolbox
Feb 7, 2020 05:30PM VolitionRx Announces Filing of Registration Statements
Jan 13, 2020 09:00AM Volition Develops a New Improved Nu.Q™ Assay Format
Jan 10, 2020 08:00AM VolitionRx Completes Acquisition of Octamer GmbH
Dec 16, 2019 08:30AM VolitionRx Limited Announces Strategic Acquisition
Dec 5, 2019 08:30AM VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test
Dec 3, 2019 08:30AM VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia
Nov 13, 2019 03:54AM VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update
Nov 12, 2019 04:10PM VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update
Nov 7, 2019 08:30AM VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update
Oct 29, 2019 08:30AM Volition announces $500,000 in Non-Dilutive Funding for Volition Veterinary and issues Video
Oct 25, 2019 12:00PM Texas A&M University Takes A 12.5% Equity Stake in Volition Veterinary Diagnostics Development LLC
Oct 18, 2019 08:30AM Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas
Oct 9, 2019 04:06PM Volitionrx Limited (VNRX) Names Dr. Phillip Barnes to Board
Oct 9, 2019 04:05PM Volition Appoints Dr. Phillip Barnes to Board of Directors
Sep 17, 2019 08:37AM Volitionrx Limited (VNRX) Reports Breakthrough in Enrichment of Tumor Nucleosomes
Sep 17, 2019 08:35AM Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes
Sep 5, 2019 06:40AM Companies with NDRs 09/05
Aug 12, 2019 04:05PM VolitionRx Limited Announces Second Quarter 2019 Financial Results and Business Update
Aug 8, 2019 08:30AM Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer
Aug 7, 2019 08:45AM VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update
Jul 24, 2019 04:05PM Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock
Jul 18, 2019 08:30AM VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China
Jul 10, 2019 08:30AM VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding
May 8, 2019 04:05PM VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update
May 7, 2019 08:30AM VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer
May 6, 2019 04:05PM VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update
Apr 9, 2019 05:17PM VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report
Apr 9, 2019 08:32AM Volitionrx Limited (VNRX) Signs MOU with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics
Apr 9, 2019 08:30AM VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics
Apr 3, 2019 08:30AM VolitionRx Limited Extends Clinical Trial Program in Lung Cancer
Mar 25, 2019 08:40AM VolitionRx Limited to Present at Conferences in March & April 2019
Mar 15, 2019 08:30AM VolitionRx Limited to Present at Conferences in the U.S. Next Week
Mar 13, 2019 04:05PM VolitionRx Limited Announces Full Fiscal Year 2018 Financial Results and Business Update
View More Recent Stories View Older Stories